Trials / Completed
CompletedNCT02169349
Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer
Advancing Monitoring of NSCLC Treated With Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor (TKI) - Molecular Diagnosis on Circulating Tumor DNA
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- Rennes University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to develop an ultra sensitive assay of mutation detection on circulating tumor DNA (ctDNA) for treatment, diagnosis and monitoring disease progression of Non-Small Cell Lung Cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | laboratory biomarker analysis | |
| OTHER | Next Generation Sequencing | |
| GENETIC | DNA Analysis |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2016-06-01
- Completion
- 2016-09-01
- First posted
- 2014-06-23
- Last updated
- 2016-09-12
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02169349. Inclusion in this directory is not an endorsement.